Of these strategies, an analogous phase I/II study has been completed for the combination of low-dose IV decitabine, venetoclax, and quizartinib in patients with relapsed/refractory FLT3 mutated AML (Table 2).54 The ORR was 78% with a median OS of 7.6 months. The gene discussed is FLT3; the disease is acute myeloid leukemia.